CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Company Data

Name CERo Therapeutics Holdings, Inc. - Common Stock

Company CERo Therapeutics Holdings, Inc.

Symbol CERO

Website https://www.cero.bio

Primary Exchange

NASDAQ

ISIN US71902K1051

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Christopher B. Ehrlich

Country United States of America

Currency USD

Employees 0,0 T

Address 201 Haskins Way, 94080 South San Francisco

IPO Date 2021-11-30

Stock Splits

Date	Split
13.06.2025	1:20
08.01.2025	1:100

ID Changes

Date	From	To
15.02.2024	PBAX	CERO

Ticker Symbols

Name	Symbol
NASDAQ	CERO

More Shares

Investors who hold CERo Therapeutics Holdings, Inc. - Common Stock also have the following shares in their portfolio:

ASIA OR.S CONS. Share

NATIONWIDE BUILDING SOCIETY 1.618% SER 16-02 CVD BDS 28/01/41 Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog